Takeda Cuts Outlook, While Astellas Get Boost

Takeda Pharmaceutical Co. lowered its earnings outlook as it deals with streamlining costs after last year's $13.7 billion acquisition of Swiss drug maker Nycomed, while rival Astellas Pharma Inc. appears headed toward a new growth phase.Although initial costs will likely weigh heavily on Takeda's earnings, Japan's biggest drug maker by sales is aiming to reap the benefits of the largest acquisition in its history as Japanese drug makers seek overseas growth to compensate for the lackluster home market and a wave of patent expirations.